Treatment of congenital adrenal hyperplasia
CRF 1 receptor antagonists have the potential to directly inhibit ACTH release in patients with CAH and thereby allow normalization of androgen production while using lower, more physiologic doses of hydrocortisone, and thus reducing treatment-associated side effects.
1. A method of treating Congenital Adrenal Hyperplasia (CAH), said method comprising administering to a subject in need thereof an effective amount of a CRF 1 receptor antagonist, wherein the CRF 1 receptor antagonist is 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-(2-propyn-1-yl)-2-thiazolamine (SSR-125543), or a pharmaceutically acceptable salt thereof.
2. The method of claim 1 , wherein the CRF 1 receptor antagonist is administered at bedtime.
3. The method of claim 1 , wherein the CRF 1 receptor antagonist is administered at or before the expected circadian release of ACTH.
4. The method of claim 1 , wherein the CRF 1 receptor antagonist is administered 3-4 hours before the expected circadian release of ACTH.
5. The method of claim 1 , wherein the CRF 1 receptor antagonist is 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-(2-propyn-1-yl)-2-thiazolamine (SSR-125543).